Neurogene (NGNE) Long-Term Investments (2014 - 2017)
Neurogene posted quarterly Long-Term Investments of $20.0 million for Q1 2017, down 48.2% year-on-year from $38.6 million in Q1 2016, and down 60.02% on a QoQ basis from $50.0 million in Q4 2016.
Neurogene (NGNE) has 4 years of Long-Term Investments data on file, last reported at $20.0 million in Q1 2017.
- For the quarter ending Q1 2017, Long-Term Investments fell 48.2% year-over-year to $20.0 million; the trailing twelve-month figure through Mar 2017 stood at $20.0 million (down 48.2% YoY), and the FY2016 full-year result was $50.0 million, up 30.13% from the prior year.
- Long-Term Investments for Q1 2017 stood at $20.0 million, down from $50.0 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $50.0 million in Q4 2016 and bottomed at $2.0 million in Q4 2014.
- The 4-year median for Long-Term Investments is $20.0 million (2017), against an average of $24.8 million.
- The widest annual swing landed in 2015, when Long-Term Investments jumped 1820.02%; it then sank 48.2% in 2017.
- A 4-year view of Long-Term Investments shows it stood at $2.0 million in 2014, then surged by 1820.02% to $38.5 million in 2015, then soared by 30.13% to $50.0 million in 2016, then slumped by 60.02% to $20.0 million in 2017.
- The last three Long-Term Investments figures came in at $20.0 million (Q1 2017), $50.0 million (Q4 2016), and $16.7 million (Q3 2016), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 505,194.89 |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 5.75 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 9.79 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 22.17 Mn |
| 10 | Neurogene | 632.14 Mn | 632.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2017 | 20.01 Mn |
| Dec 31, 2016 | 50.05 Mn |
| Sep 30, 2016 | 16.67 Mn |
| Jun 30, 2016 | 32.66 Mn |
| Mar 31, 2016 | 38.62 Mn |
| Dec 31, 2015 | 38.46 Mn |
| Dec 31, 2014 | 2.00 Mn |
| Sep 30, 2014 | 8.14 Mn |
| Jun 30, 2014 | 16.49 Mn |